Neonatal Osteopenia Of Prematurity: Prevention And Monitoring
Neonatal osteopenia of prematurity, also called metabolic bone disease of prematurity, develops when an infant’s mineral supply does not match the rapid bone growth expected during late gestation. Calcium and phosphorus transfer from the placenta accelerates in the third trimester, so babies born very early may begin life with limited skeletal mineral stores.
The condition may be clinically silent at first. A premature infant can appear stable while biochemical changes progress, which makes nutritional planning, growth assessment, and targeted laboratory monitoring important parts of neonatal care. Severe disease can contribute to reduced bone mineralization, fractures, chest-wall deformity, and delayed motor progress.
The subject fits naturally within the scientific focus of the FAOPS 2020 congress archive, which covered perinatal and neonatal medicine, clinical practice, and related research. Prevention is most effective when neonatologists, nurses, dietitians, pharmacists, and families share a consistent plan from the neonatal intensive care unit through discharge.
Why premature infants lose bone mineral
Fetal bone mineralization depends heavily on placental transfer during the final weeks of pregnancy. Infants born before approximately 32 weeks, particularly those with a very low birth weight, miss part of this transfer. Their kidneys, gastrointestinal tract, and endocrine systems must also adapt to mineral delivery outside the womb.
Several clinical factors increase the risk. Prolonged parenteral nutrition may provide inadequate calcium or phosphorus, while feeding interruptions reduce total nutrient intake. Necrotizing enterocolitis, sepsis, cholestasis, chronic lung disease, and poor growth can prolong nutritional vulnerability. Medications such as systemic corticosteroids and loop diuretics may further affect bone turnover or mineral balance.
Osteopenia is therefore a multifactorial disorder rather than a simple sign of low calcium. A baby can have a normal serum calcium concentration while drawing minerals from bone to maintain the blood level. Phosphate deficiency is particularly important because it can stimulate bone loss and increase alkaline phosphatase activity.
Prevention starts with mineral planning
Nutritional prevention begins as soon as the infant is clinically able to receive carefully prescribed nutrition. Parenteral nutrition should provide appropriate amounts of calcium and phosphorus, with attention to compatibility, solubility, fluid volume, and the infant’s renal and hepatic function. The exact prescription depends on gestational age, weight, postnatal age, and local neonatal guidance.
Early human milk is valuable for immune and developmental reasons, yet unfortified breast milk may not provide enough calcium, phosphorus, protein, and energy for very preterm infants. Human milk fortifier is commonly introduced when enteral feeding is sufficiently established. Preterm formula is another option when human milk is unavailable or insufficient, although feeding decisions should reflect tolerance, family preference, and clinical circumstances.
Vitamin D supports calcium absorption and skeletal health, but the dose should follow institutional protocols and account for all sources, including fortifier and formula. Excessive supplementation can be harmful. A written nutrition review should therefore identify the infant’s total calcium, phosphorus, protein, energy, and vitamin D intake rather than considering any nutrient in isolation.
Feeding support protects bone health
Progressive enteral feeding reduces dependence on parenteral nutrition and helps establish a reliable mineral supply. Feed advancement must remain individualized because rapid increases are inappropriate for an unstable infant or one with signs of feeding intolerance. A dietitian or neonatal pharmacist can calculate delivered, rather than merely prescribed, nutrient amounts when feeds are interrupted or diluted.
Human milk remains central to many neonatal feeding plans. Families may need practical support with expressing, storing, and maintaining milk supply during a long admission. Guidance on breastfeeding during infectious illness, including the COVID-19 breastfeeding guidance, illustrates the importance of protecting lactation while applying appropriate infection-control measures. Current local policy should always guide precautions.
Poor postnatal growth is a warning sign that deserves investigation, but weight alone can mislead. Fluid shifts, edema, diuretic use, and changes in body composition may obscure inadequate lean tissue gain. Length and head circumference, plotted by corrected gestational age on suitable preterm growth charts, provide a broader view of nutritional progress.
Monitoring bone and mineral status
No single test diagnoses every case of metabolic bone disease. Serum phosphate and alkaline phosphatase are commonly used screening markers, while calcium may remain normal even when bone mineralization is impaired. Alkaline phosphatase naturally rises in infancy, so results need to be interpreted according to postnatal age, laboratory ranges, trends, and the infant’s clinical risk.
Many units consider persistently low phosphate and substantially elevated alkaline phosphatase a reason for further assessment, but numerical thresholds vary between guidelines and laboratories. Additional tests may include calcium, magnesium, parathyroid hormone, renal function, and urinary calcium or phosphate indices. These tests can help distinguish inadequate intake from renal losses, vitamin D-related problems, or other metabolic conditions.
Radiographs are not ideal for routine screening because visible bone changes may appear only after significant mineral loss. Imaging becomes more useful when there is suspected fracture, marked biochemical abnormality, chest-wall concern, reduced limb movement, or another clinical indication. A careful examination remains important: irritability during handling, swelling, crepitus, poor limb movement, and respiratory deterioration can signal an occult fracture.
| Monitoring area | What to assess | Why it matters |
|---|---|---|
| Growth | Weight, length, and head circumference using corrected age | Detects inadequate nutrient delivery and growth faltering |
| Feeding intake | Actual calcium, phosphorus, protein, energy, and vitamin D delivery | Shows whether the prescribed plan is being achieved |
| Blood tests | Phosphate and alkaline phosphatase, with selected additional tests | Identifies biochemical patterns requiring review |
| Clinical examination | Limb movement, tenderness, swelling, chest shape, and handling tolerance | May reveal fracture or advanced skeletal weakness |
| Follow-up | Repeat review after interventions and near or after discharge | Confirms whether bone health and growth are improving |
Responding to abnormal results
When screening suggests impaired mineralization, the first step is a complete nutrition and medication review. Clinicians should verify feed volumes, fortifier preparation, interruptions, parenteral nutrition composition, and actual daily intake. They should also review diuretics, corticosteroids, cholestasis, renal function, and conditions that increase nutrient requirements.
Supplementation may involve additional calcium, phosphorus, vitamin D, or a change in feeding strategy. These interventions require supervision because excessive phosphate can cause complications, calcium and phosphate can precipitate in solutions, and renal impairment changes safe dosing. The objective is to correct the underlying imbalance while maintaining adequate protein and energy for tissue growth.
Laboratory trends are more informative than a single isolated result. A falling phosphate concentration or rising alkaline phosphatase may warrant earlier reassessment, whereas stable values with improving growth can support continuation of the existing plan. If results are discordant, consultation with a neonatologist, pediatric endocrinologist, metabolic specialist, or clinical dietitian can help clarify the diagnosis.
Coordinating care beyond the intensive care unit
Bone mineralization continues to develop after discharge, so a discharge plan should state the feeding regimen, fortification or formula instructions, supplements, growth targets, and scheduled laboratory review. Families need clear directions about preparation because incorrect mixing can reduce nutrient delivery or create unsafe concentrations. The plan should also identify who will review results and when.
Follow-up should be tailored to gestational age, birth weight, biochemical findings, ongoing respiratory disease, feeding method, and growth pattern. Some infants need repeat phosphate and alkaline phosphatase testing after discharge, particularly if they leave hospital with persistent risk factors or require nutritional supplementation. Others may be monitored primarily through growth and clinical assessment.
Practical prevention depends on a small number of reliable actions:
- Identify very preterm and very low-birth-weight infants for early bone-health review.
- Calculate delivered calcium, phosphorus, protein, energy, and vitamin D at regular intervals.
- Use fortified human milk or an appropriate preterm formula when clinically indicated.
- Track weight, length, and head circumference with corrected-age growth references.
- Investigate persistent biochemical abnormalities, poor growth, or signs of fracture promptly.
A coordinated pathway reduces variation between shifts and prevents abnormal results from being overlooked. It also gives parents a meaningful role in care, from supporting human milk feeding to recognizing changes in movement, comfort, or feeding tolerance.
Every neonatal service can strengthen outcomes by pairing a nutrition protocol with risk-based laboratory surveillance and a documented discharge plan. Clinicians, researchers, and families can use the FAOPS resource to keep perinatal practice connected to the wider evidence base, then apply that knowledge through careful daily assessment of each premature infant.
